29-Aug-2012 - Verona Pharma plc

US Patent Granted for Verona Pharma’s RPL554

Verona Pharma plc announced that the United States Patent and Trademark Office has granted a new patent for the Company’s lead drug candidate, RPL554. The patent is the fourth patent issued for RPL554 and related compounds in the US.

RPL554, Verona Pharma's lead drug candidate, is a dual phosphodiesterase 3 and 4 inhibitor with both bronchodilator and anti-inflammatory properties. RPL554 is being developed for the treatment of patients with chronic respiratory diseases such as chronic obstructive pulmonary disease (COPD) and asthma.  The Company is currently carrying out clinical trials of the drug to further characterize its bronchodilator and anti-inflammatory effects.

Dr Jan-Anders Karlsson, CEO of Verona Pharma, said: “We are growing the intellectual property portfolio around the RPL554 programme and the issue of this new US Patent strengthens and harmonizes our international patent estate around RPL554 and provides exclusivity in one of the world’s leading pharmaceutical markets. We continue to develop our intellectual property rights as this is a key part of Verona Pharma’s strategy.”

Facts, background information, dossiers
  • Verona Pharma
  • U.S. Patent & Trade…
  • patents
More about Verona Pharma
More about U.S. Patent & Trademark Office
  • News

    PBL awared further US patents on short RNAi molecules

    Plant Bioscience Limited (PBL) announced that the United States Patent and Trademark Office (USPTO) has issued US Patent No. 8,759,102 and US Patent No. 8,779,236 with fundamental claims directed to RNAi in cells and organisms to effect gene silencing. These two new patents granted add to t ... more

    PBL awarded two US patents on RNAi

    Plant Bioscience Limited (PBL) announced that the United States Patent and Trademark Office (USPTO) has issued out US Patent No. 8,258,285 with fundamental claims directed to compositions to effect gene silencing and US Patent No. 8,263,569 with fundamental claims directed to methods of ind ... more

    New Patents Issued to Diffusion Pharmaceuticals

    Diffusion Pharmaceuticals LLC announced that the U.S. Patent and Trademark Office has granted it patent numbers 7919527 and 8030350, entitled “Bipolar Trans Carotenoids Salts and Their Uses” and “Trans Carotenoids, Their Synthesis and Uses,” respectively. These patents include compound, com ... more